Microbot Medical (MBOT) Oppenheimer 36th Annual Healthcare MedTech & Services Conference summary

Market overview and unmet needs

• Endovascular robotic-assisted surgery is a largely untapped market with only one other cleared competitor, offering significant growth potential in the U.S. and globally.

• The U.S. endovascular market sees 5–6 million procedures annually, with a focused group of 15,000 physicians and 8,000 facilities.

• Major unmet needs include radiation safety, ergonomic challenges, and limited access to experienced care, especially in rural areas.

• Barriers to adoption have included long setup times, steep learning curves, high capital costs, and large equipment footprints.

• 75% of surveyed interventionalists expect to adopt robotic systems within 1–3 years.

Product innovation and differentiation

• The LIBERTY Endovascular Robotic System is the first fully disposable, single-use robotic system, eliminating capital and infrastructure costs.

• Setup time averages less than two minutes, with no need for service contracts or dedicated infrastructure.

• The system is compatible with standard guide wires and catheters, requiring minimal training and integrating easily into existing workflows.

• Clinical studies showed 100% navigation success, 92% reduction in radiation exposure, and high user satisfaction.

• The business model is based on recurring consumable revenue, not capital sales.

Commercialization progress and strategy

• FDA clearance was obtained in September 2025, with a limited U.S. market release starting in November 2025.

• Initial customers include Emory University Hospital and Tampa General Hospital, with additional accounts pending announcement.

• Most procedures to date are performed by interventional radiologists, focusing on embolization and cancer treatments.

• The sales cycle is significantly shortened due to the lack of capital investment requirements.

• Full market release is scheduled for mid-April 2026, with expansion from four to twelve U.S. territories by year-end.